'What does success look like for growing life sciences companies; is it aligned with what industry needs?’
During this round-table discussion our speakers will share their thoughts on the key areas that company leaders need to get right in order to achieve success - above and beyond excellent science. This includes an evolving strategy, deliverable targets, establishing a safe and inclusive environment, engaging in mutually beneficially collaborations that can transform R&D, being open to and adopting new technologies and complying with new standards and regulations.
After introductory keynotes, we will invite guests to contribute to a round-table discussion on whether a company's expectation of success meets that of the industry.
08.30 - 09.00 Guest arrival and breakfast served
09.00 - 09.30 Introductions & keynotes from:
Introduction from Stuart Rose, CEO of OBN
Matthew Beard PhD, Senior Director External Innovation at Ipsen
Sarah Pollitt, Independent Pharma & Healthcare Strategic Advisor
Joe Illingworth, Director & Co-Founder at DJS Antibodies
09.30 - 10.30 Round table discussion with all guests and speakers, facilitated by OBN
About OBN's C-Suite Events:
OBN's round table C-Suite Events are designed exclusively for senior C-Suite leaders (or equivalent) from life sciences organisations, whether R&D or those involved in providing critical support services to the industry.
The purpose of these events is to generate some interesting, useful, high-level and boundary pushing discussion and debate, that creates some practical thought-leadership output.
Please note that places are limited and will be offered on an approval only basis.
Director, Research and Co-founder of DJS Antibodies
Joe is the CSO and Co-Founder of DJS Antibodies. Joe loves working in a small and focussed team to solve problems creatively. He was a leader in the establishment of HEPTAD, the mAb discovery engine at the heart of DJS, and now oversees all R&D activities within the company. His work covers mAb discovery and screening through to preclinical development of lead drugs, and he works closely with industry-leading experts as well as managing several government funded projects. Joe holds a BSc in Biochemistry from Imperial College London and a PhD in antibody discovery and characterisation from the University of Oxford. After studying Joe worked as an academic on antibody induction and vaccination. In his spare time he loves playing the guitar, sailing, kicking a football around and growing vegetables.
Ipsen was first established as a business in the UK in 1981, and in Ireland in 1989. Today, the UK & Ireland forms a critical and growing part of our Global network and is one of our core operating hubs alongside Cambridge, M.A., USA and Paris, France. As a UK & Ireland Hub we are collaborating to deliver outcomes for patients, health services and our community of current and future colleagues. Three of Ipsen’s leading medicines are manufactured in the UK & Ireland, with our UK footprint also ‘home’ to the global neuroscience franchise, with neurotoxin research, development, and manufacturing capabilities located across our Milton Park (Oxford) and Wrexham facilities.